Vitor Carmona

Vitor Carmona

Auto-generated profile, based on publicly available information

Vitor Carmona

CNC—Center for Neuroscience and Cell Biology University of Coimbra Coimbra Portugal

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
DRDavid Rufino-Ramos
David Rufino-Ramos
PAPatrícia R. Albuquerque
Patrícia R. Albuquerque
VCVitor Carmona
Vitor Carmona
RPRita Perfeito
Rita Perfeito
RNRui Nobre
Rui Nobre
LALuis Pereira De Almeida
Luis Pereira De Almeida

11 May 2016 in Nature Communications
Verified
Journal Article
Open access
JCJanete Cunha-Santos
Janete Cunha-Santos
JDJoana Duarte-Neves
Joana Duarte-Neves
VCVitor Carmona
Vitor Carmona
LGLeonard Guarente
Leonard Guarente
LALuis Pereira De Almeida
Luis Pereira De Almeida
CCCláudia Cavadas
Cláudia Cavadas
Machado–Joseph disease (MJD) is a neurodegenerative disorder characterized by an abnormal expansion of the CAG triplet in the ATXN3 gene, translating into a polyglutamine tract within the ataxin-3 protein. The available treatments only ameliorate symptomatology and do not block disease progression. In this study we find that caloric restriction dramatically rescues the motor incoordination, imbalance and the associated neuropathology in transgenic MJD mice. We further show that caloric restriction rescues SIRT1 levels in transgenic MJD mice, whereas silencing SIRT1 is sufficient to prevent the beneficial effects on MJD pathology. In addition, the re-establishment of SIRT1 levels in MJD mouse model, through the gene delivery approach, significantly ameliorates neuropathology, reducing neuroinflammation and activating autophagy. Furthermore, the pharmacological activation of SIRT1 with resveratrol significantly reduces motor incoordination of MJD mice. The pharmacological SIRT1 activation could provide important benefits to treat MJD patients.

1 April 2017 in Molecular Therapy
Verified
Journal Article
Open access
VCVitor Carmona
Vitor Carmona
JCJanete Cunha-Santos
Janete Cunha-Santos
IOIsabel Onofre
Isabel Onofre
ASAna Teresa Simões
Ana Teresa Simões
UVUdaya Vijayakumar
Udaya Vijayakumar
LALuis Pereira De Almeida
Luis Pereira De Almeida
Machado-Joseph disease (MJD) is a genetic neurodegenerative disease caused by an expanded polyglutamine tract within the protein ataxin-3 (ATXN3). Despite current efforts, MJD's mechanism of pathogenesis remains unclear and no disease-modifying treatment is available. Therefore, in this study, we investigated (1) the role of the 3' UTR of ATXN3, a putative microRNA (miRNA) target, (2) whether miRNA biogenesis and machinery are dysfunctional in MJD, and (3) which specific miRNAs target ATXN3-3' UTR and whether they can alleviate MJD neuropathology in vivo. Our results demonstrate that endogenous miRNAs, by targeting sequences in the 3' UTR, robustly reduce ATXN3 expression and aggregation in vitro and neurodegeneration and neuroinflammation in vivo. Importantly, we found an abnormal MJD-associated downregulation of genes involved in miRNA biogenesis and silencing activity. Finally, we identified three miRNAs-mir-9, mir-181a, and mir-494-that interact with the ATXN3-3' UTR and whose expression is dysregulated in human MJD neurons and in other MJD cell and animal models. Furthermore, overexpression of these miRNAs in mice resulted in reduction of mutATXN3 levels, aggregate counts, and neuronal dysfunction. Altogether, these findings indicate that endogenous miRNAs and the 3' UTR of ATXN3 play a crucial role in MJD pathogenesis and provide a promising opportunity for MJD treatment.

1 December 2017 in Cell Reports
Verified
Journal Article
Open access
LHLea J. Hachigian
Lea J. Hachigian
VCVitor Carmona
Vitor Carmona
RFRobert J. Fenster
Robert J. Fenster
RKRuth Kulicke
Ruth Kulicke
AHAdrian Heilbut
Adrian Heilbut
MHMyriam Heiman
Myriam Heiman
Alteration of corticostriatal glutamatergic function is an early pathophysiological change associated with Huntington's disease (HD). The factors that regulate the maintenance of corticostriatal glutamatergic synapses post-developmentally are not well understood. Recently, the striatum-enriched transcription factor Foxp2 was implicated in the development of these synapses. Here, we show that, in mice, overexpression of Foxp2 in the adult striatum of two models of HD leads to rescue of HD-associated behaviors, while knockdown of Foxp2 in wild-type mice leads to development of HD-associated behaviors. We note that Foxp2 encodes the longest polyglutamine repeat protein in the human reference genome, and we show that it can be sequestered into aggregates with polyglutamine-expanded mutant Huntingtin protein (mHTT). Foxp2 overexpression in HD model mice leads to altered expression of several genes associated with synaptic function, genes that present additional targets for normalization of corticostriatal dysfunction in HD.

10 February 2018
Verified
Book Chapter
Closed access
PDF file
CMCarlos A. Matos
Carlos A. Matos
VCVítor Carmona
Vítor Carmona
UVUdaya-Geetha Vijayakumar
Udaya-Geetha Vijayakumar
SLSara Lopes
Sara Lopes
PAPatrícia Albuquerque
Patrícia Albuquerque
LALuis Pereira De Almeida
Luis Pereira De Almeida

17 July 2021 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Closed access
PDF file
ASAna Teresa Simões
Ana Teresa Simões
VCVítor Carmona
Vítor Carmona
JDJoana Duarte‐Neves
Joana Duarte‐Neves
JCJanete Cunha‐Santos
Janete Cunha‐Santos
LALuis Pereira De Almeida
Luis Pereira De Almeida